NYXH Nasdaq

Equities

NYXH

End-of-day quote Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2022	Nyxoah's Q1 Loss Widens, Revenue Increases	MT
2022	Oppenheimer Starts Nyxoah at Outperform With $30 Price Target	MT

Lock

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about NYXH

Nyxoah's Q1 Loss Widens, Revenue Increases	10/05/22	MT
Oppenheimer Starts Nyxoah at Outperform With $30 Price Target	21/04/22	MT
Wolfe Research Starts Nyxoah at Peer Perform With $21 Price Target	06/04/22	MT
Piper Sandler Adjusts Price Target on Nyxoah to $30 From $40, Reiterates Overweight Rating	28/03/22	MT
NYXH : Nyxoah's Genio System Obtains CE-Mark Indication Approval to Treat Complete Concentric Collapse	05/10/21	MT
NYXH : Nyxoah Secures Breakthrough Therapy Designation for Genio Nerve Stimulation Device	14/09/21	MT
NYXH : Nyxoah Reports Wider Loss in H1	31/08/21	MT
NYXH : Stifel Initiates Nyxoah With Buy Rating	27/07/21	MT
Sector Update: Health Care Stocks Posting Gains Ahead of Friday Close	02/07/21	MT
Sector Update: Health Care	02/07/21	MT
NYXH : Belgium's Nyxoah Shares Rise in Stock Market Debut	02/07/21	MT
NYXH : Nyxoah Prices US IPO at $30 Per Share	02/07/21	MT

Chart NYXH

Duration

Period

Company Profile

Sector

-

More about the company

Our Free Content Help you Secure and Increase the Performance of Your Investments

Secure my Investments

fermer